SHC Sotera Health Company
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Sotera Health Company (NASDAQ: SHC)
›
Sotera Health Company (NASDAQ: SHC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 3,000 employees.
The shares were at 16.21 USD on 19 November 2026, down 1.3% over 52 weeks. Its 52-week range is 13.09 USD to 19.85 USD: the price is 18.3% below the high and 23.8% above the low.
At a market capitalisation of 4.63B USD, it trades at 27.0 times trailing earnings and 15.2 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 24% for SHC.
Sotera Health Company reports return on equity of 12.9%, an operating margin of 36.8% and revenue up 4.4% year over year.
Its debt exceeds its cash by 1.86B USD, a debt-to-equity ratio of 3.75. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 21.44 USD is 32.3% above the current price. The next earnings report is expected on 23 February 2027.